tbuckley/cabot-search huggingface dataset:
OS5.8 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG)
Authors: A. M. Zukas, N. Bennani, C. Chou, P. Johnston, B. O’Neill, M. Nijland, T. Batchelor, L. Nayak, M. Mrugala, D. Schiff
Journal: Neuro-Oncology (2016)
Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).
Authors: Jumei Shi, Guido Tricot, Susann Szmania, Cristyn Camet, Nancy Rosen, Michele Cottler-Fox, Bart Barlogie, Dario Campana, Frits van Rhee
Journal: Blood (2005)
Survival is associated with circulating cytokine levels in metastatic testicular germ cell tumors
Authors: D. Svetlovska, V. Miskovska, D. Cholujova, P. Gronesova, S. Cingelova, M. Chovanec, Z. Sycova-Mila, J. Obertova, P. Palacka, J. Rajec, K. Kalavska, V. Usakova, J. Luha, D. Ondrus, S. Spanik, J. Mardiak, M. Mego
Journal: Annals of Oncology (2016)
The association of metal air pollutants with lung cancer risk
Authors: Yvonne Coyle, Abu T. Minhajuddin, Linda S. Hynan, John D. Minna
Journal: Cancer Research (2006)

4559  Air pollution particulate matter (PM) is associated with lung cancer risk. Copper, iron, nickel, vanadium, and zinc are in airborne PM, and cadmium, nickel, and zinc are in tobacco smoke. Cadmium and nickel, as well as several other metals released into air by industry are human lung carcinogens. We conducted an ecological study to examine the association of industrial air releases for metals with lung cancer incidence in Texas. During 1995-2000, 81,132 lung cancer cases were reported in Texas. We identified metals that: (1) are in airborne PM or tobacco smoke, or are human lung carcinogens, and (2) had consistent Environmental Protection Agency reporting for air releases for multiple counties during 1988-2000. We examined the association of metal air releases with average annual age-adjusted rates for lung and non-small cell lung cancer, and lung adenocarcinoma at the county level. Univariate analysis indicated the following positive associations: (1) zinc with the lung cancer (p = 0.02), non-small cell lung cancer (p
OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101
Authors: W. Wick, R. Stupp, T. Gorlia, M. Bendszus, A. A. Brandes, M. J. Voss, E. Le Rhun, P. M. Clement, V. Golfinopoulos, M. van den Bent
Journal: Neuro-Oncology (2016)

This trial aimed at evaluating the optimal treatment sequence (single agent vs sequential vs combination) of lomustine (LOM) and bevacizumab (BEV) in a randomized phase II design. Progressive patients after standard of care were randomized 2:2:2:1 between Arm 1: LOM 90 mg/m2 (max. 160 mg) every 6 weeks plus BEV (10 mg/kg) every 2 weeks until progression, subsequent salvage treatment at the investigators best choice (MD choice); Arm 2: LOM 110 mg/m2 (max. 200 mg) every 6 weeks, at progression switch to BEV every two weeks; Arm 3: BEV every 2 weeks, at progression add LOM 90 mg/m2 (max. 160 mg) every 6 weeks and continue BEV; and Arm 4: LOM single agent 110 mg/m2 (max. 200 mg) every 6 weeks, at progression MD choice (arm 4). Eligibility criteria included performance status 0–2, adequate hematological, liver and renal function, and an interval since the end of radiotherapy of ≥ 3 months to rule out pseudoprogression. The primary endpoint was overall survival at 12 months (OS12), progression free survival (PFS) was measured from the start of study treatment until 1st PD according RANO criteria. Between Oct 2011 and July 2013 274 patients were randomized. Baseline characteristics were well balanced, and all treatment generally well tolerated. In arm 4, 43% received subsequent salvage BEV. Time to first progression was longer in initially BEV treated patients, but survival was similar in all arms: Study treatment (per protocol population) n OS 12 (95% CI) Med OS Med PFS Arm 1: LOM+BEV ◊ MD choice 70 32.9% (25.4, 41.1) 9.1 mo 4.2 mo Arm 2: LOM, ◊ BEV 73 27.4% (20.6, 35.2) 7.8 mo 1.5 mo Arm 3: BEV, ◊ LOM+BEV 70 32.9% (25.4, 41.1) 7.9 mo 2.8 mo Arm 4: LOM, ◊ MD choice 36 41.7% (30.4, 53.7) 9.3 mo 1.6 mo Initially BEV treated patients had longer PFS, but OS 12 or median OS were similar in the various schedules of BEV and LOM. Agnostic of this data, the emerging BELOB study data triggered this trial to be continued as a phase III comparing LOM versus BEV plus LOM.
Early Lymphocyte Recovery Predicts Superior Survival after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation for Patients with Hematological Malignancies.
Authors: Ying jun Chang, Xiang yu Zhao, Ming rui Huo, Lan ping Xu, Dai hong Liu, Kai yan Liu, Xiao Jun Huang
Journal: Blood (2008)
The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients
Authors: Christian Kellner, Eugene A Zhukovsky, Monika Brüggemann, Michael Kneba, André Schrauder, Martin Schrappe, Roland Repp, Andreas Humpe, Martin Gramatzki, Matthias Peipp
Journal: Blood (2012)
endocrine and neuroendocrine tumours 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasms
Authors: M. Rinzivillo, F. Panzuto, G. Capurso, D. Prosperi, P. Pizzichini, E. Iannicelli, E. Pilozzi, E. Merola, N. Cicchese, F. Scopinaro, O. Schillaci, Glle De Fave
Journal: Annals of Oncology (2016)
2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection
Authors: Hugues de Lavallade, Paula Lorraine Garland, Takuya Sekine, Katja Hoschler, David Marin, Kate Stringaris, Eva Loucaides, Katherine Howe, Richard M. Szydlo, Edward J. Kanfer, Donald McDonald, Peter Kelleher, Nichola Cooper, Ahmad Khoder, Ian H Gabriel, Abdullah Alsuliman, Dragana Milojkovic, Jiri Pavlu, John M. Goldman, Jane F. Apperley, Katayoun Rezvani
Journal: Blood (2010)
A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548
Authors: M. Weller, G. Vlahovic, M. Khasraw, A.A. Brandes, R. Zwirtes, K. Tatsuoka, A.F. Carpentier, D.A. Reardon, Mvanden Bent
Journal: Annals of Oncology (2016)
Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca/Bcl-XL Plasma Cell Malignancy.
Authors: Michael Fitzgerald, Yueying Cao, Bret Bannerman, Zhi Li, Olga Tayber, Ping Li, Jennifer Terkelsen, Daniel Bradley, Jonathan Frazer, Lee Silverman, Siegfried Janz, Brian G Van Ness, Erik Kupperman, Mark Manfredi, Edmund Lee
Journal: Blood (2009)
Divergent Regulation of Hepatic Glucose and Lipid Metabolism by Phosphoinositide 3-Kinase via Akt and PKCλ/ζ
Authors: Cullen M. Taniguchi, Tatsuya Kondo, Mini Sajan, Ji Luo, Roderick Bronson, Tomoichiro Asano, Robert Farese, Lewis C. Cantley, C. Ronald Kahn
Journal: Cell Metabolism (2016)
Rapid Pacing–Induced Right Ventricular Dysfunction Is Evident After Balloon-Expandable Transfemoral Aortic Valve Replacement
Authors: Richard G. Axell, Paul A. White, Joel P. Giblett, Lynne Williams, Bushra S. Rana, Andrew Klein, Michael O’Sullivan, William R. Davies, Cameron G. Densem, Stephen P. Hoole
Journal: Journal of the American College of Cardiology (2017)
P07.15 Diagnostic value of 2-hydroxyglutarate detection by 1H MR spectroscopy in patients with glioma and correlations with tumor phenotype and tissue dosage
Authors: A. L. Di Stefano, F. Branzoli, C. Ottolenghi, L. Capelle, K. Mokhtari, C. M. Villa, M. Giry, M. Marjanska, S. Lehericy, M. Sanson
Journal: Neuro-Oncology (2016)
QLIF-26. ASSESSING THE RELATIONSHIP BETWEEN VINCRISTINE USE AND OUTCOMES IN A RETROSPECTIVE COHORT OF PEDIATRIC PATIENTS WITH AVERAGE RISK MEDULLOBLASTOMAS
Authors: Dazhi Liu, Cheryl Fischer, Mary Petriccione, Debra Goldman, Elyn Riedel, Kevin De Braganca
Journal: Neuro-Oncology (2016)

To assess the relationship between vincristine use and outcomes in pediatric patients with average risk medulloblastoma who were on the cisplatin/lomustine/vincristine regimen. Treatment of average risk medulloblastoma in pediatric patients includes surgery followed by radiation and vincristine and then adjuvant chemotherapy. Post-radiation chemotherapy includes eight cycles of cisplatin, lomustine and vincristine. Some patients have vincristine doses omitted or reduced due to toxicities and the impact of this on survival is unknown. We reviewed all patients with medulloblastoma who received treatment at MSK from July 1993 to June 2016. Patients with average risk medulloblastoma who received radiation therapy and cisplatin, lomustine and vincristine containing regimen post surgery are included in the study. Patients with high risk medulloblastoma, treated with other regimen or with incomplete medical information were excluded. Overall Survival (OS) and Event Free Survival (EFS) were estimated at 5 years using Kaplan Meier estimates with 95% confidence intervals. The relationships between vincristine use and OS/EFS were assessed using Cox proportional hazard regression with time dependent covariates. One hundred and ninety-nine patients with medulloblastoma were identified in the pediatric neuro oncology clinical database. Forty-eight patients with standard risk medulloblastoma and received cisplatin/lomustine/vincristine regimen post surgery and radiation. Only one patient received no vincristine and fifteen patients (31%) received complete induction and maintenance vincristine. The major reason for incomplete vincristine was peripheral neuropathy, present in 18 patients (37.5%). Neither vincristine omission nor completion was found to be significantly associated with OS (p=0.43->0.95) or EFS (p=0.08-0.53). Vincristine was omitted or the dose was reduced in the majority of patients. Incomplete vincristine use was not found to be associated with OS or EFS.
IMST-14. IDH1 R132H MUTATION INHIBITS ANTI-GLIOMA IMMUNE RESPONSES THROUGH POST-TRANSCRIPTIONAL DOWN-REGULATION OF STAT1 AND TYPE-1 CHEMOKINES
Authors: Gary Kohanbash, Shruti Shrivastav, Brian Ahn, Diego Carrera, Naznin Jahan, Casey Beppler, Nduka Amankulor, Joseph F. Costello, Hideho Okada
Journal: Neuro-Oncology (2016)

We evaluated whether isocitrate dehydrogenase (IDH) mutations could directly alter the immune landscape of gliomas, possibly through production of the onco-metabolite, 2-hydroxygluterate (2HG). TCGA RNAseq data demonstrate reduced expression of CD8 T-cell, type-1 effector and chemokine genes in IDH-mutated (Mut) patients compared to IDH-wild-type (Wt) cases. Conversely, we observed no differences in B-cell, type-2 or regulatory T-cell-related genes between IDH-Wt and IDH-Mut cases. Normal human astrocyte (NHA) cells and syngeneic GL261 glioma models expressing the R132H mutated IDH1 (NHA-Mut and GL261-Mut, respectively) further demonstrated that the IDH1 mutation and 2HG directly reduce CXCL10 protein and migration of T-cells to the tumor site, which was reversed by an IDH-specific inhibitor, IDH-C35. Further, while mice receiving prophylactic peptide vaccination targeting glioma-associated antigens resulted in clearance of GL261-Wt tumors, vaccinated mice could not reject GL261-Mut tumors. Treatment of vaccinated mice bearing GL261-Mut tumors with IDH-C35 enhanced anti-tumor immunity and prolonged survival compared to mice receiving vaccine alone. Interestingly, both parental GL261 cells treated with 2HG and GL261-Mut cells demonstrated decreased amounts of STAT1 protein but not mRNA compared with untreated GL261-Wt cells, suggesting that STAT1, a known regulator of CXCL10, is regulated at the post-transcriptional level in IDH-Mut gliomas. Consistent with these findings, TCGA microRNA data demonstrated increased levels of miR-145, a known regulator of STAT1, in IDH-Mut compared with IDH-Wt cases. We next evaluated direct tumor extrinsic implications of the IDH1 mutation. 2HG, which is known to be present in the tumor microenvironment, directly induced a ~10 fold increase in miR-145-5p and reduced both STAT1 levels and CXCL10 secretion from primary and BV2 murine microglia. Our findings demonstrate both glioma-intrinsic and extrinsic mechanisms of immunosuppression in IDH-Mut gliomas and suggest that IDH inhibitors can be used to enhance T-cell migration to the tumor site in patients with IDH-Mut tumors.
Microrna 124 and Its Role in Response to Epigenetic Therapy in Patients with Acute Mylogenous Leukemia and Myelodysplastic Syndrome
Authors: Ryan J Castoro, Mhair Dekmezian, Amanda J Saraf, Yoshiyuki Watanabe, Woonbok Chung, Samih El Adhab, Jaroslav Jelinek, Jean-Pierre Issa
Journal: Blood (2008)
Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study
Authors: Y. Sukawa, K. Nosho, Y. Miura, T. Takano, M. Ito, K. Yonesaka, M. Mori, S. Tokunaga, J. Kawada, H. Okuda, T. Sakamoto, Y. Hirashima, K. Uchino, Y. Miyata, K. Yoshimura, K. Yamazaki, S. Hironaka, N. Boku, I. Hyodo, K. Muro
Journal: Annals of Oncology (2016)
Molecular Characterization of Human CML Cells with Resistance to the Heat Shock Protein (hsp) 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin (17-AAG).
Authors: Purva Bali, Warren Fiskus, Fei Guo, Srinivas Annavarapu, Celia Sigua, Gautam Sondarva, Abdelmoughite Mouttaki, Peter Atadja, Paul Manley, Kapil N. Bhalla
Journal: Blood (2004)
Drug-drug interactions in cancer patients: a prospective study of medication surveillance on cytotoxic agents
Authors: A.E. Ramos-Esquivel, A. Viquez-Jaikel, C. Fernandez, Z. Zeledon, F. Jimenez, M. Juarez, L. Corrales, I. Gonzalez-Herrera
Journal: Annals of Oncology (2016)
Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics
Authors: E. Schwalbe, D. Hicks, G. Rafiee, M. Bashton, H. Gohlke, A. Enshaei, S. Potluri, J. Matthiesen, M. Mather, P. Taleongpong, R. Chaston, S. Crosier, A. Smith, D. Williamson, S. Bailey, S. Clifford
Journal: Annals of Oncology (2016)
EPID-20. ACCESS TO SUBSPECIALTY CARE AND SURVIVAL AMONG PATIENTS WITH GLIOBLASTOMA IN THE BRONX: THE MONTEFIORE MEDICAL CENTER EXPERIENCE
Authors: Nina Massad, Juhi Purswani, Patrick Lasala, Nitin Ohri, Jerome Graber, Mary Welch
Journal: Neuro-Oncology (2016)

Management of brain tumor patients requires a multidisciplinary approach. Treatment entails surgery followed by chemotherapy and radiation (RT). Studies have demonstrated improved outcomes when surgery is performed by high-volume providers who specialize in brain cancer, but little data exists on the impact of specialization in post-operative management. MMC serves a diverse and economically challenged population. In 2011, it established the Bronx’s first division of neuro-oncology. As part of a QI initiative designed to identify barriers to care among patients with brain cancer, we retrospectively identified patients over age 20 diagnosed with glioblastoma (GBM) from 2005-2014. Clinical and demographic characteristics were collected including age, gender, performance status (KPS), English proficiency, ethnicity, insurance coverage, laterality, extent of surgery (biopsy vs. resection), RT and access to a sub-specialist. Log-rank was used to test for equality of survivor functions. Cox regression analysis was performed on predictors of mortality. Two hundred and four patients were included. Median age was 63 (range, 20-97); 113 (55%) were men; and 30 (15%) had KPS <60. A majority (64%) self-classified as white/non-Hispanic; 23% had limited proficiency in English; only 25% had private insurance. A third of patients underwent biopsy only and 36 (19%) never initiated RT. Ninety-seven patients (48%) were managed in the community; 43 (21%) went elsewhere -- typically to a center with sub-specialty care; 64 (31%) were managed by MMC neuro-oncologists after 2011. Median overall survival (OS) for the cohort was 10.5 months (CI: 8.5-12) with median follow-up of 10.5 months. Univariate cox regression showed no difference in OS based on ethnicity, gender or insurance status. On multivariate analysis, only RT (HR 0.51; CI, 0.33-0.81) and access to neuro-oncologists (HR 0.54; CI, 0.37-0.79) were associated with improved outcomes. Access to providers with subspecialty training in neuro-oncology can improve outcomes for GBM patients.
Validation of New Prognostic Model Including Comorbidities in Patients with Myleodysplastic Syndrome Receiving Hypomethylating Therapy
Authors: Young-Don Joo, Je-Hwan Lee, Sung-Doo Kim, Yunsuk Choi, Young-Hun Park, Jae Seok Lee, Dae-Young Kim, Jung-Hee Lee, Kyoo-Hyung Lee, Won Sik Lee, Sang Min Lee
Journal: Blood (2011)
Sf3b1 K700E Mutation Impairs Pre-mRNA Splicing and Definitive Hematopoiesis in a Conditional Knock-in Mouse Model
Authors: Annalisa Mupo, Vijitha Sathiaseelan, Michael Seiler, David Kent, Shouyong Peng, Ruben Bautista, Suruchi Pacharne, Barry Rosen, Manousos Koutsourakis, Nicla Manes, Frances Law, Elli Papaemmanuil, Silvia Buonamici, Peter J Campbell, Niccolo Bolli, George S. Vassiliou
Journal: Blood (2015)
Radioimmunotherapy (RIT) with 90y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens
Authors: Barbara Botto, Marilena Bellò, Annalisa Chiappella, Roberto Passera, Giulia Benevolo, Carola Boccomini, Maria Giuseppina Cabras, Claudia Castellino, Giuseppe Fioritoni, Chiara Frairia, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Umberto Ricardi, Giovanni Bisi, Umberto Vitolo
Journal: Blood (2008)
MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology
Authors: N. Mach, R. Vernet, M.-C. Belkouch, P. Luy, V. Ancrenaz, P. Teta, N. Blazek, N. Grandjean, J. Wasem, J. Grogg, T. Perez, D. Migliorini
Journal: Annals of Oncology (2016)

Cell Encapsulation Technology (CET) allows the standardized release of GM-CSF by genetically modified allogeneic cells loaded within a capsule. We present the final results of the Phase I clinical trial assessing this patient specific, cell-based therapy, combining the implantation of irradiated autologous tumor cells and capsules containing allogeneic cells genetically engineered to produce huGM-CSF. For this single center, first in human Phase 1 trial, 15 pts with progressing, solid tumors refractory to all standard treatments were enrolled. Immunizations was performed in healthy skin, distant from tumor deposits. Patients were treated with 6 sc immunizations (week 1-2-3-4-6-8) combining 4x106 irradiated autologous tumor cells and 2 capsules containing 8x105 MVX-1 cells, producing >20ng/24h of huGM-CSF. Capsules were removed after 8 days and analyzed for huGM-CSF production. Primary endpoints are safety and feasibility. Secondary endpoints include clinical outcome and immunomonitroing. 15 patients are available for safety and feasibility. Tt is very well tolerated with only one G3 AE related to IMP. Main toxicity is G1-2 minor discomfort during caspules sc implantation. No treatment related SAE were reported. Clinical grade therapeutic products were successfully manufactured for all patients. 95% % of explanted macrocapsules showed good ex-vivo huGM-CSF production. >50% of patients (8/15) experienced either PR or SD including disappearance of lung metastasis, prolong survival. Correlation between positive DTH and OS was observed. Immunomonitoring by Elispot shows increased INFg production by PBMC after immunization. MVX-ONCO-1 is the first personalized cell-based immunotherapy combining autologous tumor cells and sustained local production of GM-CSF at the vaccination site using cell encapsulation technology. This technology has a very good safety profile safe with no systemic SAE related to therapy. In this heavily pretreated population, clinical activity (partial response and stable disease ) was observed in >50 of patients.
Adoptively Transferred Central Memory Derived Human CD8+Effectors Exhibit Superior Engraftment Fitness Over Their Naïve T Cell Derived Counterparts
Authors: Xiuli Wang, ChingLam W Wong, Brenda Aguilar, Wen-Chung Chang, Julie R Ostberg, Stanley R. Riddell, Stephen J. Forman, Michael C. Jensen
Journal: Blood (2011)
NIMG-44. IMPACT OF DELAYED CONTRAST ENHANCED CT SCANS (CECT) ON GROSS TUMOR VOLUME (GTV) IN GLIOBLASTOMA (GBM)
Authors: Narendra Kumar, Kanchan K. Mukherjee, Sameer Vyas, Nikesh Hanumanthappa, Anindya Mukherjee, Renu Madan
Journal: Neuro-Oncology (2016)

Treatment of GBM has evolved from whole brain radiotherapy (RT) to involved field RT. MRI is remaining the gold standard for defining the target volume in GBM despite the availability and affordability. The standard of care is to fuse MRI with planning CT for target delineation. We are investigating target delineation without MRI in low resource set up. From Feb 2011 to Jan 2014, eighty out of 218 patients of Glioblastoma were analyzed who had all three sequences, e.g. Pre-Radiotherapy T1W contrast MRI, 15 seconds & 10 Minutes post contrast planning CT scan. Planning CECT images were acquired after 15 seconds & 10 minutes post IV contrast with adequate immobilization. Target was delineated in all three sequences separately. Target was defined as contrast enhanced lesions and surgical cavity excluding surrounding edema in consensus with radiologist & Neurosurgeon. Three target volumes were abbreviated as GTV_Immediate, GTV_Delayed, and GTV_MRI. Mean time to acquire post-surgery MRI and Radiotherapy Planning CECT was 45 (range 33-60) days and 50(range 30-60) days. Mean target volume of immediate, delayed, and MRI were 41.20cc (0 – 140cc), 58.20cc (4.57-165.35cc) and 63.78cc (5.41-200cc), respectively. Mean volumes were compared with paired T-test between immediate Vs. Delayed, Delayed Vs. MRI and volume difference between Immediate & Delayed Vs. volume difference between Delayed & MRI which showed p < 0.0001 (df=79,CI=19.58-12.4), p < 0.0001 (df=79, CI=10.1-3.05), and p < 0.0001(df=79,CI=14.87-7.32) respectively. Though MRI is the gold standard for target delineation in GBM, MRI acquired in non-ideal conditions may cause a gross increase in the target volume. Delayed CECT can help in fairly estimating the actual target volume and sometimes underlines the limitations of MRI. Based on our results we may propose a delayed RT planning CECT in place of Immediate CECT for target volume delineation in glioblastoma.
Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma
Authors: S. Martin-Algarra, J.B. Haanen, C. Horak, S. Bhatia, A. Ribas, W.-J. Hwu, C.L. Slingluff,, W.H. Sharfman, M. Callahan, F.S. Hodi, J.D. Wolchok, J. Luke, T.C. Young, A. Qureshi, W.J. Urba
Journal: Annals of Oncology (2016)
Outcomes of 40 Adult Patients after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Conditioning Regimen.
Authors: Karen K. Ballen, Corey Cutler, Thomas R. Spitzer, Beow Yeap, Steve McAfee, Bimalangshu R. Dey, Eyal Attar, Richard L. Haspel, Edwin Alyea, Vincent Ho, Robert J. Soiffer, Joseph H. Antin
Journal: Blood (2006)
Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)
Authors: Mark C. Gillies, Vincent Daien, Vuong Nguyen, Daniel Barthelmes
Journal: Ophthalmology (2017)
A predictive model for diagnosis of lower extremity cellulitis: A cross-sectional study
Authors: Adam B. Raff, Qing Yu Weng, Jeffrey M. Cohen, Nicole Gunasekera, Jean-Phillip Okhovat, Priyanka Vedak, Cara Joyce, Daniela Kroshinsky, Arash Mostaghimi
Journal: Journal of the American Academy of Dermatology (2017)